Gonçalo Forjaz1, Jill S Barnholtz-Sloan2,3, Carol Kruchko2, Rebecca Siegel4, Serban Negoita1, Quinn T Ostrom2,5, Lois Dickie1, Jennifer Ruhl1, Alison Van Dyke1, Nirav Patil2, Gino Cioffi2,3, Kimberly D Miller4, Kristin Waite2,3, Angela B Mariotto1. 1. Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA. 2. Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA. 3. Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 4. Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia, USA. 5. Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Abstract
BACKGROUND: There are over 100 histologically distinct types of primary malignant and nonmalignant brain and other central nervous system (CNS) tumors. Our study presents recent trends in the incidence of these tumors using an updated histology recode that incorporates major diagnostic categories listed in the 2016 World Health Organization Classification of Tumours of the CNS. METHODS: We used data from the SEER-21 registries for patients of all ages diagnosed in 2000-2017. We calculated age-adjusted incidence rates and fitted a joinpoint regression to the observed data to estimate the Annual Percent Change and 95% confidence intervals over the period 2000-2017. RESULTS: There were 315,184 new malignant (34.2%; 107,890) and nonmalignant (65.8%; 207,294) brain tumor cases during 2004-2017. Nonmalignant meningioma represented 46.5% (146,498) of all brain tumors (malignant and nonmalignant), while glioblastoma represented 50.8% (54,832) of all malignant tumors. Temporal trends were stable or declining except for nonmalignant meningioma (0.7% per year during 2004-2017). Several subtypes presented decreases in trends in the most recent period (2013-2017): diffuse/anaplastic astrocytoma (-1.3% per year, oligodendroglioma (-2.6%), pilocytic astrocytoma (-3.8%), and malignant meningioma (-5.9%). CONCLUSIONS: Declining trends observed in our study may be attributable to recent changes in diagnostic classification and the coding practices stemming from those changes. The recode used in this study enables histology reporting to reflect the changes. It also provides a first step toward the reporting of malignant and nonmalignant brain and other CNS tumors in the Surveillance, Epidemiology, and End Results (SEER) Program by clinically relevant histology groupings.
BACKGROUND: There are over 100 histologically distinct types of primary malignant and nonmalignant brain and other central nervous system (CNS) tumors. Our study presents recent trends in the incidence of these tumors using an updated histology recode that incorporates major diagnostic categories listed in the 2016 World Health Organization Classification of Tumours of the CNS. METHODS: We used data from the SEER-21 registries for patients of all ages diagnosed in 2000-2017. We calculated age-adjusted incidence rates and fitted a joinpoint regression to the observed data to estimate the Annual Percent Change and 95% confidence intervals over the period 2000-2017. RESULTS: There were 315,184 new malignant (34.2%; 107,890) and nonmalignant (65.8%; 207,294) brain tumor cases during 2004-2017. Nonmalignant meningioma represented 46.5% (146,498) of all brain tumors (malignant and nonmalignant), while glioblastoma represented 50.8% (54,832) of all malignant tumors. Temporal trends were stable or declining except for nonmalignant meningioma (0.7% per year during 2004-2017). Several subtypes presented decreases in trends in the most recent period (2013-2017): diffuse/anaplastic astrocytoma (-1.3% per year, oligodendroglioma (-2.6%), pilocytic astrocytoma (-3.8%), and malignant meningioma (-5.9%). CONCLUSIONS: Declining trends observed in our study may be attributable to recent changes in diagnostic classification and the coding practices stemming from those changes. The recode used in this study enables histology reporting to reflect the changes. It also provides a first step toward the reporting of malignant and nonmalignant brain and other CNS tumors in the Surveillance, Epidemiology, and End Results (SEER) Program by clinically relevant histology groupings.
Authors: Therese A Dolecek; Emily Van Meter Dressler; Jigisha P Thakkar; Meng Liu; Abeer Al-Qaisi; John L Villano Journal: Cancer Date: 2015-04-14 Impact factor: 6.860
Authors: E Susan Amirian; Renke Zhou; Margaret R Wrensch; Sara H Olson; Michael E Scheurer; Dora Il'yasova; Daniel Lachance; Georgina N Armstrong; Lucie S McCoy; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Jonine L Bernstein; Ryan T Merrell; Faith G Davis; Rose Lai; Sanjay Shete; Christopher I Amos; Beatrice S Melin; Melissa L Bondy Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-02 Impact factor: 4.254
Authors: Felix Sahm; David Reuss; Christian Koelsche; David Capper; Jens Schittenhelm; Stephanie Heim; David T W Jones; Stefan M Pfister; Christel Herold-Mende; Wolfgang Wick; Wolf Mueller; Christian Hartmann; Werner Paulus; Andreas von Deimling Journal: Acta Neuropathol Date: 2014-08-21 Impact factor: 17.088
Authors: Diana R Withrow; Amy Berrington de Gonzalez; Clara J K Lam; Katherine E Warren; Meredith S Shiels Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-11-21 Impact factor: 4.254
Authors: Joellen M Schildkraut; Lisa Calvocoressi; Frances Wang; Margaret Wrensch; Melissa L Bondy; Joseph L Wiemels; Elizabeth B Claus Journal: J Neurosurg Date: 2014-01-31 Impact factor: 5.408